There is a little known company that is changing warfare

With geo - political instability around the world investors are flocking to defense contract stocks. There is a little known company that is changing warfare. With the backing of U.S. government contracts, this startup is reshaping the future of the U.S. military.

Click here to gain instant access to one of the most exclusive pre-ipo opportunities in the market t

Richard B. Doubleday net worth and biography

Richard Doubleday Biography and Net Worth

EVP of DexCom

Richard B. Doubleday is no longer serves as Executive Vice President, Chief Commercial Officer of the Company effective 12/31/2020. He has served as our Executive Vice President, Chief Commercial Officer since January 2015. From February 2013 to January 2015, Mr. Doubleday served as our Senior Vice President of Worldwide Sales and Marketing. From June 2009 to February 2013, Mr. Doubleday served as our Vice President of Sales. From May 1988 to June 2009, Mr. Doubleday served in various roles for Johnson & Johnson, Inc. (“J&J”), including Director of Marketing for J&J subsidiary Animas Corporation, a manufacturer of insulin pumps, from July 2006 to June 2009, and Field Sales Director for J&J subsidiary LifeScan, Inc., a manufacturer of blood glucose monitoring systems, from August 2002 to October 2005. Mr. Doubleday received a B.A. from Michigan State University.

What is Richard B. Doubleday's net worth?: The estimated net worth of Richard B. Doubleday is at least $1.61 million as of March 23rd, 2021. Mr. Doubleday owns 21,554 shares of DexCom stock worth more than $1,609,653 as of November 14th. This net worth evaluation does not reflect any other investments that Mr. Doubleday may own. Learn More about Richard B. Doubleday's net worth.
How do I contact Richard B. Doubleday?: The corporate mailing address for Mr. Doubleday and other DexCom executives is 6340 SEQUENCE DRIVE, SAN DIEGO CA, 92121. DexCom can also be reached via phone at (858) 200-0200 and via email at [email protected]. Learn More on Richard B. Doubleday's contact information.
Has Richard B. Doubleday been buying or selling shares of DexCom?: Richard B. Doubleday has not been actively trading shares of DexCom during the last quarter. Most recently, Richard Doubleday sold 1,109 shares of the business's stock in a transaction on Tuesday, March 23rd. The shares were sold at an average price of $360.49, for a transaction totalling $399,783.41. Following the completion of the sale, the executive vice president now directly owns 21,554 shares of the company's stock, valued at $7,770,001.46. Learn More on Richard B. Doubleday's trading history.
Who are DexCom's active insiders?: DexCom's insider roster includes Donald Abbey (EVP), Steven Altman (Director), Nicholas Augustinos (Director), Andrew Balo (Insider), Quentin Blackford (COO), Michael Brown (EVP), Richard Collins (Director), Matthew Dolan (SVP), Richard Doubleday (EVP), Paul Flynn (EVP), Mark Foletta (Director), Bridgette Heller (Director), Barbara Kahn (Director), Jacob Leach (EVP), Jeffrey Moy (EVP), Patrick Murphy (EVP), Steven Pacelli (Insider), Chad Patterson (EVP), Barry Regan (EVP), Kevin Sayer (CEO), Shelly Selvaraj (SVP), Sumi Shrishrimal (SVP), Jay Skyler (Director), Sadie Stern (EVP), and Jereme Sylvain (CAO). Learn More on DexCom's active insiders.
Are insiders buying or selling shares of DexCom?: During the last twelve months, insiders at the medical device company sold shares 29 times. They sold a total of 253,409 shares worth more than $33,229,896.21. The most recent insider tranaction occured on September, 9th when EVP Sadie Stern sold 426 shares worth more than $29,457.90. Insiders at DexCom own 0.3% of the company. Learn More about insider trades at DexCom.
Information on this page was last updated on 9/9/2024.

Richard B. Doubleday Insider Trading History at DexCom

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
3/23/2021	Sell	1,109	$360.49	$399,783.41	21,554
1/4/2021	Sell	11,025	$366.06	$4,035,811.50
4/23/2020	Sell	1,530	$318.57	$487,412.10	51,482
2/24/2020	Sell	1,532	$277.75	$425,513.00	48,444
1/23/2020	Sell	1,532	$234.34	$359,008.88	48,444
11/22/2019	Sell	1,533	$217.56	$333,519.48	48,444
10/23/2019	Sell	1,533	$152.34	$233,537.22
8/23/2019	Sell	2,016	$175.14	$353,082.24	72,570
7/23/2019	Sell	2,016	$153.56	$309,576.96	72,570
3/25/2019	Sell	2,016	$127.38	$256,798.08	72,570
11/23/2018	Sell	1,736	$121.35	$210,663.60	66,804
7/23/2018	Sell	2,581	$102.48	$264,500.88	94,429
6/25/2018	Sell	2,581	$98.58	$254,434.98	94,429
5/23/2018	Sell	2,581	$86.00	$221,966.00	94,429
4/23/2018	Sell	2,581	$73.09	$188,645.29	94,429
3/23/2018	Sell	2,581	$68.44	$176,643.64	94,429
2/23/2018	Sell	1,638	$56.32	$92,252.16	65,049
1/23/2018	Sell	1,635	$54.67	$89,385.45	65,049
12/26/2017	Sell	1,635	$56.39	$92,197.65	65,049
11/24/2017	Sell	1,635	$55.53	$90,791.55	65,049
10/23/2017	Sell	1,635	$44.82	$73,280.70	65,049
8/23/2017	Sell	1,635	$75.26	$123,050.10	72,395
5/23/2017	Sell	3,182	$68.29	$217,298.78	72,395
4/24/2017	Sell	3,182	$75.78	$241,131.96	97,815
3/23/2017	Sell	3,182	$76.38	$243,041.16	97,815
2/23/2017	Sell	3,182	$78.42	$249,532.44	83,582
1/23/2017	Sell	3,182	$79.50	$252,969.00	83,582
12/23/2016	Sell	3,182	$62.17	$197,824.94	83,582
9/23/2016	Sell	3,182	$93.97	$299,012.54	83,582
7/25/2016	Sell	3,182	$87.31	$277,820.42	92,250
5/23/2016	Sell	1,674	$63.59	$106,449.66	94,900
4/25/2016	Sell	1,666	$69.15	$115,203.90	94,900
3/23/2016	Sell	1,666	$61.76	$102,892.16	123,022
2/23/2016	Sell	1,666	$64.36	$107,223.76	100,483
12/23/2015	Sell	1,666	$82.22	$136,978.52	100,483
11/23/2015	Sell	1,666	$85.85	$143,026.10	100,483
10/23/2015	Sell	1,666	$79.27	$132,063.82	100,483
7/23/2015	Sell	9,641	$85.37	$823,052.17
5/27/2015	Sell	3,258	$70.73	$230,438.34
3/12/2015	Sell	20,000	$59.23	$1,184,600.00
2/23/2015	Sell	4,000	$63.58	$254,320.00
1/23/2015	Sell	4,000	$58.22	$232,880.00
12/23/2014	Sell	4,000	$54.69	$218,760.00
11/24/2014	Sell	4,000	$50.36	$201,440.00
10/23/2014	Sell	4,000	$43.58	$174,320.00
9/23/2014	Sell	4,000	$40.32	$161,280.00
8/25/2014	Sell	4,000	$44.35	$177,400.00
8/19/2014	Sell	20,000	$45.01	$900,200.00
7/23/2014	Sell	4,000	$38.16	$152,640.00
6/23/2014	Sell	4,000	$40.98	$163,920.00
6/5/2014	Sell	4,000	$35.59	$142,360.00
4/23/2014	Sell	4,000	$35.92	$143,680.00	147,523
5/9/2013	Sell	1,272	$19.56	$24,880.32
3/11/2013	Sell	5,100	$15.63	$79,713.00

Richard B. Doubleday Buying and Selling Activity at DexCom

DexCom Company Overview

DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions. It has also submitted FDA review for Dexcom Stelo for people with type 2 diabetes. The company has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. It markets its products directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999 and is headquartered in San Diego, California.

Today's Range

Now: $74.68

$71.75

$75.78

50 Day Range

MA: $69.77

$65.68

$74.85

2 Week Range

Now: $74.68

$62.34

$142.00

Volume

4,192,267 shs

Average Volume

3,919,698 shs

Market Capitalization

$29.17 billion

P/E Ratio

44.72

Dividend Yield

N/A

Beta

1.17